FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new derivatives of indol-3-yl of the formula (I):
wherein each A and B represents independently of one another oxygen atom (O), NH, CONH, NHCO or a direct bond; X means (C1-C2)-alkylene or a direct bond; R1 means hydrogen atom (H); R2 means hydrogen atom (H); R3 means NHR6, -NR6-C(=NR6)-NHR6, -C(=NR6)-NHR6, -NR6-C(=NR9)-NHR6, -C(=NR9)-NHR6 or Het1; each R4 and R5 represents independently of one another hydrogen atom (H); R7 means -(CH2)o-Ar, Het, OR6; R6 means hydrogen atom (H); R7 means (C1-C10)-alkyl, (C3-C10)-cycloalkyl; R8 means Hal, NO2 (nitro-group), CN (cyano-group), Z, -(CH2)o-Ar, COOR1, OR1, CF3, OCF3, NHR1; R9 means CN or NO2; Z means (C1-C6)-alkyl; Ar means aryl that can represent unsubstituted, monosubstituted, or polysubstituted R8; Hal means F, Cl, Br, J; Het means saturated, partially or completely saturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members wherein 1 or 2 nitrogen atom (N) and/or 1 or two sulfur atom (S) present, and heterocyclic radical can be monosubstituted with phenyl; Het1 means saturated, partially or completely unsaturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members and from 1 to 4 nitrogen atoms (N) that can be unsubstituted or monosubstituted NHX, or oxo-group; n = 0, 1 or 2; m = 0, 1, 2, 3, 4, 5 or 6; o means 0, 1 or 2; and their physiologically acceptable salts and solvates. Compounds of the formula (I) elicit intergin-inhibitory effect that allows their using as components of pharmaceutical composition. Also, invention describes intermediate compounds.
EFFECT: valuable medicinal properties of compounds.
11 cl, 4 sch, 1 tbl, 34 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF CHROMENONE AND CHROMANONE AS INTEGRIN INHIBITORS | 1999 |
|
RU2234505C2 |
AROMATIC 6,7-DISUBSTITUTED 3-QUINOLINECARBOXAMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USE THEREOF IN DRUG MANUFACTURING | 2002 |
|
RU2281940C2 |
DERIVATIVES OF INDOLE OR BENZIMIDAZOLE FOR MODULATION OF IkB KINASE | 2003 |
|
RU2318820C2 |
PYRIDINE DERIVATIVES CONDENSED WITH HETEROCYCLE | 1996 |
|
RU2136683C1 |
MACROCYCLIC UREA AND SULPHAMIDE DERIVATIVES AS TAFIa INHIBITORS | 2009 |
|
RU2502736C2 |
NITROGEN-CONTAINING HETEROARYL DERIVATIVES | 2011 |
|
RU2559895C2 |
SUBSTITUTED INDOLES | 2000 |
|
RU2255087C2 |
OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENT | 2008 |
|
RU2450001C2 |
Authors
Dates
2005-07-27—Published
2001-01-05—Filed